Login to Your Account



Amgen Q2 beat expectations, boosts full-year guidance

By Michael Fitzhugh
Staff Writer

Friday, July 31, 2015

Amgen Inc. shares (NASDAQ:AMGN) briefly hit a record high of $181.81 on Friday as the drugmaker reported a higher-than-expected second quarter profit, driven in part by strong sales of Enbrel (etanercept), Prolia and Xgeva (denosumab) and cost-cutting. The drugmaker also raised its full-year guidance as it moved to launch new products, such as the world’s first approved PCSK9 inhibitor, Repatha (evolocumab).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription